BEAT Stock Price, BioTelemetry Inc Quote, Chart

Market Summary

USD2.09-0.02

Market Closed

-0.95%

BEAT Stock Price

View Fullscreen

BEAT RSI Chart

BEAT Valuation

Market Cap

55.6M

Price/Earnings (Trailing)

-3.68

EV/EBITDA

-2.84

Price/Free Cashflow

-4.38

MarketCap/EBT

-3.68

BEAT Price/Sales (Trailing)

BEAT Profitability

Return on Equity

-120.51%

Return on Assets

-110.81%

Free Cashflow Yield

-22.86%

BEAT Fundamentals

BEAT Earnings

Earnings (TTM)

-15.1M

Earnings Growth (Yr)

-11.36%

Earnings Growth (Qtr)

-18.74%

Breaking Down BEAT Revenue

52 Week Range

1.883.74

(Low)(High)

Last 7 days

5.0%

Last 30 days

17.2%

Last 90 days

26.4%

Trailing 12 Months

-3.2%

How does BEAT drawdown profile look like?

BEAT Financial Health

BEAT Investor Care

Shares Dilution (1Y)

1.65%

Diluted EPS (TTM)

-0.49

Tracking the Latest Insider Buys and Sells of BioTelemetry Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 29, 2023	de urioste george	sold	-11,330	2.06	-5,500	-
Sep 28, 2023	de urioste george	sold	-16,320	2.04	-8,000	-
Sep 27, 2023	de urioste george	sold	-3,869	2.11	-1,834	-
Sep 26, 2023	de urioste george	sold	-10,450	2.09	-5,000	-
Sep 22, 2023	de urioste george	sold	-5,288	2.21	-2,393	-
Sep 21, 2023	de urioste george	sold	-241	2.41	-100	-
Sep 20, 2023	de urioste george	sold	-2,172	2.46	-883	-
Sep 18, 2023	de urioste george	sold	-12,300	2.46	-5,000	-
Sep 15, 2023	de urioste george	sold	-10,373	2.43	-4,269	-
Sep 14, 2023	de urioste george	sold	-10,850	2.17	-5,000	-

Which funds bought or sold BEAT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-11,097	142,295	-%
May 15, 2024	MORGAN STANLEY	added	33.21	3,336	17,490	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-62.00	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	25.00	25.00	-%
May 15, 2024	AE Wealth Management LLC	sold off	-100	-24,148	-	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	unchanged	-	-74,500	125,000	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-64.76	-13,344	6,481	-%
May 15, 2024	Lee Financial Co	sold off	-100	-2,350	-	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	3,795	3,795	-%
May 14, 2024	ADVISORY RESEARCH INC	unchanged	-	-8,500	109,000	0.02%

Are Funds Buying or Selling BEAT?

Are funds buying BEAT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BEAT

No. of Funds

Unveiling BioTelemetry Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Oct 25, 2023	strome mark e	12.0%	3,150,000	SC 13D
Aug 28, 2023	public ventures, llc	9.41%	2,624,910	SC 13D
Jun 02, 2023	schwartzberg andrew	7.33%	1,899,536	SC 13D
Feb 13, 2023	ionic ventures, llc	0.52%	41,519	SC 13G/A
Jan 10, 2023	sabby management, llc	3.40%	271,788	SC 13G/A
Feb 03, 2022	ionic ventures, llc	9.99%	813,522	SC 13G/A
Mar 10, 2021	arrowmark colorado holdings llc	0.0%	0	SC 13G/A
Feb 16, 2021	arrowmark colorado holdings llc	11.4%	3,927,595	SC 13G/A
Feb 10, 2021	vanguard group inc	10.16%	3,486,540	SC 13G/A
Jan 25, 2021	blackrock inc.	15.6%	5,368,860	SC 13G

Recent SEC filings of BioTelemetry Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 03, 2024	424B5	Prospectus Filed
May 02, 2024	8-K	Current Report
Apr 30, 2024	DEF 14A	DEF 14A
Apr 19, 2024	PRE 14A	PRE 14A
Mar 20, 2024	10-K	Annual Report

Peers (Alternatives to BioTelemetry Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	479.9B	379.5B	11.20%	7.55%	31.24	1.26	12.96%	-25.81%
CI	96.4B	206.0B	-2.18%	28.90%	25.01	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	2.85%	17.20%	15.46	1.27	9.59%	-4.59%
CVS	72.2B	360.9B	-16.66%	-17.14%	9.86	0.2	9.07%	78.49%
CNC	41.2B	155.5B	6.71%	14.75%	15.05	0.26	6.34%	84.42%
UHS	12.0B	14.7B	10.86%	33.14%	14.73	0.82	7.99%	19.23%
DVA	12.0B	12.3B	5.19%	38.43%	14.68	0.97	5.77%	58.74%
MID-CAP
CHE	8.6B	2.3B	-6.84%	5.15%	30.33	3.75	5.96%	18.29%
ACHC	6.2B	3.0B	-6.14%	-7.19%	-547.09	2.07	10.92%	-104.06%
AMEH	2.3B	1.5B	8.58%	22.04%	36.93	1.59	19.34%	40.15%
AMN	2.2B	3.5B	3.96%	-38.10%	15.61	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	13.47%	25.04%	27.49	1.66	11.45%	30.74%
BKD	1.4B	3.0B	11.90%	88.00%	-7.82	0.45	4.98%	4.88%
BEAT	55.6M	-	17.22%	-3.21%	-3.68	-	-	-1.05%
AMS	21.1M	21.6M	17.97%	25.63%	38.19	0.98	9.04%	-50.63%

BioTelemetry Inc News

Latest updates

BioTelemetry Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet										(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-20.4%	13,635	17,131	19,648	4,039	6,672	9,738	12,741	13,998	961	-
Current Assets	-21.3%	13,237	16,825	19,479	4,039	-	-	-	-	-	-
Cash Equivalents	-21.6%	12,688	16,189	19,184	3,594	6,549	9,274	11,201	13,192	795	24.00
Net PPE	34.4%	344	256	144	-	-	-	-	-	-	-
Liabilities	-8.1%	1,097	1,194	1,019	1,665	932	770	514	588	6,148	4,836
Shareholder's Equity	-21.3%	12,538	15,937	18,629	2,374	5,740	8,968	12,227	13,410	-	-
Retained Earnings	-12.5%	-41,431	-36,825	-32,946	-22,186	-18,474	-14,895	-11,370	-9,224	-7,139	-4,796
Additional Paid-In Capital	2.3%	53,966	52,759	51,572	24,559	24,213	23,862	23,596	22,633	1,952	11.00
Shares Outstanding	0%	26,329	26,329	26,325	8,010	8,147	8,146	8,082	7,810	3,706	3,528
Float	-	-	-	-	-	-	6,424	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-21.2%	-3,463	-2,858	-2,098	-4,023	-3,114	-2,955	-2,725	-1,929	-2,339	-2,441	-365	-269	-155	-	-
Share Based Compensation	1.7%	1,207	1,187	926	702	393	346	351	264	159	107	53.00	23.00	9.00	-	-
Cashflow From Investing	21.4%	-88.00	-112	3,795	-3,939	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	-	-	-	111	24,373	510	-	-	2.00	348	14,838	695	650	215	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BEAT Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Expenses:
General and administrative	$ 2,356	$ 2,475
Research and development	2,428	1,681
Total operating expenses	4,784	4,156
Loss from operations	(4,784)	(4,156)
Other Income
Interest income	178	20
Total other income	178	20
Loss before provision for income taxes	(4,606)	(4,136)
Income tax provision	0	0
Net Loss	$ (4,606)	$ (4,136)
Net loss per share, basic (in dollars per share)	$ (0.17)	$ (0.50)
Net loss per share, diluted (in dollars per share)	$ (0.17)	$ (0.50)
Weighted average common shares outstanding, basic (in shares)	26,511,201	8,222,416
Weighted average common shares outstanding, diluted (in shares)	26,511,201	8,222,416

BEAT Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 12,638	$ 16,189
Prepaid expenses and other current assets	599	636
Total Current Assets	13,237	16,825
Property and equipment, net	344	256
Other assets	54	50
Total Assets	13,635	17,131
Current Liabilities:
Accounts payable and accrued expenses (includes related party $- and $2, respectively)	1,097	1,194
Total Liabilities	1,097	1,194
Commitments (Note 7)
Stockholders’ Equity
Preferred stock - $0.0001 par value; 10,000,000 authorized; 0 shares outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock - $0.0001 par value $100,000,000 shares authorized; $26,329,032 shares issued and outstanding at March 31, 2024 and December 31, 2023	3	3
Additional paid in capital	53,966	52,759
Accumulated deficit	(41,431)	(36,825)
Total Stockholders’ Equity	12,538	15,937
Total Liabilities and Stockholders’ Equity	$ 13,635	$ 17,131

About BioTelemetry Inc

HeartBeam, Inc., a medical technology company, primarily focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease inside and outside a healthcare facility setting. The company develops three-dimensional vector images of cardiac electrical activity. It is developing HeartBeam AIMIGo, a credit card-sized cloud-based diagnostic software systems to address heart attack detection. The company was incorporated in 2015 and is based in Santa Clara, California.

CEO	Dr. Branislav Vajdic Ph.D.
WEBSITE	heartbeam.com
INDUSTRY	Healthcare Plans
EMPLOYEES	10

BioTelemetry Inc Frequently Asked Questions

What is the ticker symbol for BioTelemetry Inc? What does BEAT stand for in stocks?

BEAT is the stock ticker symbol of BioTelemetry Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioTelemetry Inc (BEAT)?

As of Thu May 16 2024, market cap of BioTelemetry Inc is 55.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BEAT stock?

You can check BEAT's fair value in chart for subscribers.

What is the fair value of BEAT stock?

You can check BEAT's fair value in chart for subscribers. The fair value of BioTelemetry Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioTelemetry Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BEAT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioTelemetry Inc a good stock to buy?

The fair value guage provides a quick view whether BEAT is over valued or under valued. Whether BioTelemetry Inc is cheap or expensive depends on the assumptions which impact BioTelemetry Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BEAT.